1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Celltrion Reports Positive Rheumatoid Arthritis Data From Subcutaneous Infliximab

 
• By Akriti Seth

New data presented by Celltrion at EULAR 2019 suggest that its subcutaneous formulation of infliximab is comparable to the intravenous version in treating rheumatoid arthritis.

Hands_Arthritis
Celltrion’s subcutaneous formulation of infliximab is comparable to the intravenous version in rheumatoid arthritis • Source: Shutterstock

Celltrion Healthcare’s new subcutaneous (SC) formulation of its CT-P13 biosimilar infliximab has shown positive results for the treatment of rheumatoid arthritis (RA) compared to the intravenous version, according to the firm’s latest data.

At this year’s European Congress of Rheumatology, EULAR, the South Korean firm presented a two-part study investigating the pharmacokinetics, efficacy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.